New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with ...

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in ...

Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and ...

Already USFDA-approved, under-the-skin jab can be administered in just seven minutes to the patient. This is dramatic cut ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, ...

Meeting Coverage > GuCS Cabozantinib Plus Atezolizumab Delays Progression in mCRPC — Combination improved PFS versus more hormonal therapy, but control arm questioned by Mike Bassett, Staff ...

Meeting Coverage > WCLC New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC — Overall survival benefit now demonstrated by Leah Lawrence, Contributing Writer, MedPage Today August 9, 2022 ...

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, is already approved for the treatment of bladder cancer and small cell lung cancer (SCLC). It is also approved for use in second-line ...

Based on the data presented at ASCO 2021, the FDA approved adjuvant atezolizumab in October 2021 for patients with PD-L1–positive resected stages II and IIIA non–small cell lung cancer.

Treatment with atezolizumab resulted in a median overall survival duration of 15.9 months, with an objective response rate of 23%, rising to 28% in patients with the highest levels of PD-L1 ...